마이코플라스마 검사 시장 규모, 점유율 및 동향 분석 : 제품별, 기술별, 용도별, 최종 용도별, 지역별, 부문 예측(2025-2033년)

Mycoplasma Testing Market Summary

The global mycoplasma testing market size was estimated at USD 1.03 billion in 2024 and is expected to reach USD 2.81 billion in 2033, growing at a CAGR of 11.94% from 2025 to 2033. The rising investments in research and development (R&D) across the life sciences sector are a significant market driver.

Pharmaceutical companies are actively channeling substantial resources into biopharmaceutical and biosimilar development, which requires stringent contamination control. For instance, Bristol-Myers Squibb has invested heavily in the production of investigational medicines to support its expanding portfolio of clinical trials.

The biopharmaceutical and related markets have not been significantly impacted by the COVID-19 pandemic when compared to other industries. According to a study published in May 2022, there is a correlation between mycoplasma testing numbers and COVID-19-related Non-Pharmaceutical Interventions (NPIs). This study analyzed the incidence of M. pneumonia after the implementation of COVID-19 NPIs. This survey showed that there has been a decrease in M. pneumoniae detection during the pandemic, and a reduction was observed globally between March 2020 and March 2021. The reduction is majorly due to restricted transmission of M. pneumonia, resulting in a significant reduction in M. pneumoniae infections across the globe.

As biopharmaceutical and vaccine production scales up, manufacturers require reliable mycoplasma testing solutions to ensure the purity, safety, and regulatory compliance of their products. Consequently, the need for advanced testing kits has intensified. Moreover, as more biologics advance through clinical development, maintaining uncontaminated cell cultures becomes critical, thereby increasing the demand for rigorous mycoplasma testing. Ongoing innovations in detection technologies are also expected to yield faster, more sensitive, and cost-effective testing methods that align with the growing requirements of the pharmaceutical industry.

The rising global emphasis on public health preparedness and the expanding demand for vaccines are expected to drive strong market growth. Supporting this trend, leading pharmaceutical companies continue to invest heavily in biomanufacturing infrastructure. For example, in October 2025, Merck & Co., Inc. announced the start of construction on a USD 3 billion, 400,000-square-foot pharmaceutical manufacturing facility at its Elkton, Virginia site. This major investment underscores the industry's commitment to expanding vaccine and biologics production capacity to meet global demand.

Global Mycoplasma Testing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global mycoplasma testing market report based on product, technology, application, end-use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Instruments
• Kits & Reagents
  • PCR Assays
  • Nucleic Acid Detection Kits
  • Stains
  • Elimination Kits
  • Standards & Controls
  • Others
• Services
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• PCR
• ELISA
• Direct Assay
• Indirect Assay
• Microbial Culture Techniques
• Enzymatic Methods
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Cell Line Testing
• Virus Testing
• End of Production Cells Testing
• Others
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Academic Research Institutes
• Cell Banks
• Contract Research Organizations
• Pharmaceutical & Biotechnology Companies
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Spain
  • France
  • Italy
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Thailand
  • Australia
• Latin America
  • Brazil
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1 Market Segmentation and Scope
  • 1.1.1 Segment Definitions
    • 1.1.1.1 Test Segment
    • 1.1.1.2 Service Provider Segment
    • 1.1.1.3 Application Segment
• 1.2 Regional Scope
• 1.3 Estimates and Forecast Timeline
• 1.4 Objectives
  • 1.4.1 Objective - 1
  • 1.4.2 Objective - 2
  • 1.4.3 Objective - 3
• 1.5 Research Methodology
• 1.6 Information Procurement
  • 1.6.1 Purchased Database
  • 1.6.2 Gvr's Internal Database
  • 1.6.3 Secondary Sources
  • 1.6.4 Primary Research
• 1.7 Information or Data Analysis
  • 1.7.1 Data Analysis Models
• 1.8 Market Formulation & Validation
• 1.9 Model Details
  • 1.9.1 Commodity Flow Analysis
• 1.10 List of Secondary Sources
• 1.11 List of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Trends and Outlook
• 3.4. Market Dynamics
  • 3.4.1. Increasing R&D investments in life sciences
  • 3.4.2. Rising government support toward pharmaceutical and biotechnology industries
  • 3.4.3. Growing demand for biopharmaceuticals and vaccines
  • 3.4.4. Rising cell culture contamination
• 3.5. Market Restraint Analysis
  • 3.5.1. High cost of research in cell biology
  • 3.5.2. Slow rate of mycoplasma growth
• 3.6. Opportunity Analysis
• 3.7. Current and Future Market Trends:
• 3.8. Business Environment Analysis
  • 3.8.1. SWOT Analysis: By Factor (Political & Legal, Economic, And Technological)
  • 3.8.2. Porter's Five Forces Analysis
• 3.9. COVID-19 Impact Analysis
• 3.10. Mekko Chart for Mycoplasma Testing Market, by Product
• 3.11. Mekko Chart for Mycoplasma Testing Market, by Test Method

Chapter 4. Product Business Analysis

• 4.1. Mycoplasma Testing Market: Product Movement Analysis
• 4.2. Instruments
  • 4.2.1. Instruments Market, 2021 - 2033 (USD Million)
• 4.3. Kits & Reagents
  • 4.3.1. Kits & Reagents Market, 2021 - 2033 (USD Million)
  • 4.3.2. PCR Assays
    • 4.3.2.1. PCR Assays Market, 2021 - 2033 (USD Million)
  • 4.3.3. Nucleic Acid Detection Kits
    • 4.3.3.1. Nucleic Acid Detection Kits Market, 2021 - 2033 (USD Million)
  • 4.3.4. Stains
    • 4.3.4.1. Stains Market, 2021 - 2033 (USD Million)
  • 4.3.5. Elimination Kits
    • 4.3.5.1. Elimination Kits Market, 2021 - 2033 (USD Million)
  • 4.3.6. Standards & Controls
    • 4.3.6.1. Standards & Controls Market, 2021 - 2033 (USD Million)
  • 4.3.7. Others
    • 4.3.7.1. Others Market, 2021 - 2033 (USD Million)
• 4.4. Services
  • 4.4.1. Services Market, 2021 - 2033 (USD Million)

Chapter 5. Technology Business Analysis

• 5.1. Mycoplasma Testing Market: Technology Movement Analysis
• 5.2. PCR
  • 5.2.1. PCR Market, 2021 - 2033 (USD Million)
• 5.3. ELISA
  • 5.3.1. ELISA Market, 2021 - 2033 (USD Million)
• 5.4. Direct Assay
  • 5.4.1. Direct Assay Market, 2021 - 2033 (USD Million)
• 5.5. Indirect Assay
  • 5.5.1. Indirect Assay Market, 2021 - 2033 (USD Million)
• 5.6. Microbial Culture Techniques
  • 5.6.1. Microbial Culture Techniques Market, 2021 - 2033 (USD Million)
• 5.7. Enzymatic Methods
  • 5.7.1. Enzymatic Methods Market, 2021 - 2033 (USD Million)

Chapter 6. Application Business Analysis

• 6.1. Mycoplasma Testing Market: Application Movement Analysis
• 6.2. Cell Line Testing
  • 6.2.1. Cell Line Testing Market, 2021 - 2033 (USD Million)
• 6.3. Virus Testing
  • 6.3.1. Virus Testing Market, 2021 - 2033 (USD Million)
• 6.4. End of Production Cells Testing
  • 6.4.1. End of Production Cells Testing Market, 2021 - 2033 (USD Million)
• 6.5. Others
  • 6.5.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. End Use Business Analysis

• 7.1. Mycoplasma Testing Market: End Use Movement Analysis
• 7.2. Pharmaceutical & Biotechnology Companies
  • 7.2.1. Pharmaceutical & Biotechnology Companies Market, 2021 - 2033 (USD Million)
• 7.3. Cell Banks
  • 7.3.1. Cell Banks Market, 2021 - 2033 (USD Million)
• 7.4. Contract Research Organizations
  • 7.4.1. Contract Research Organizations Market, 2021 - 2033 (USD Million)
• 7.5. Academic & Research Institutes
  • 7.5.1. Academic & Research Institutes Market, 2021 - 2033 (USD Million)
• 7.6. Others
  • 7.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 8. Regional Business Analysis

• 8.1. Mycoplasma Testing Market Share By Region, 2024 & 2033
• 8.2. North America
  • 8.2.1. SWOT Analysis
  • 8.2.2. North America Mycoplasma Testing Market, 2021 - 2033 (USD Million)
  • 8.2.3. U.S.
    • 8.2.3.1. Key Country Dynamics
    • 8.2.3.2. Target Disease Prevalence
    • 8.2.3.3. Competitive Scenario
    • 8.2.3.4. Regulatory Framework
    • 8.2.3.5. Reimbursement Scenario
    • 8.2.3.6. U.S. Mycoplasma Testing Market, 2021 - 2033 (USD MILLION)
  • 8.2.4. Canada
    • 8.2.4.1. Key Country Dynamics
    • 8.2.4.2. Target Disease Prevalence
    • 8.2.4.3. Competitive Scenario
    • 8.2.4.4. Regulatory Framework
    • 8.2.4.5. Reimbursement Scenario
    • 8.2.4.6. Canada Mycoplasma Testing Market, 2021 - 2033 (USD Million)
  • 8.2.5. Mexico
    • 8.2.5.1. Key Country Dynamics
    • 8.2.5.2. Target Disease Prevalence
    • 8.2.5.3. Competitive Scenario
    • 8.2.5.4. Regulatory Framework
    • 8.2.5.5. Reimbursement Scenario
    • 8.2.5.6. Mexico Mycoplasma Testing Market, 2021 - 2033 (USD Million)
• 8.3. Europe
  • 8.3.1. SWOT Analysis
  • 8.3.2. Europe Mycoplasma Testing Market, 2021 - 2033 (USD Million)
  • 8.3.3. Germany
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Target Disease Prevalence
    • 8.3.3.3. Competitive Scenario
    • 8.3.3.4. Regulatory Framework
    • 8.3.3.5. Reimbursement Scenario
    • 8.3.3.6. Germany Mycoplasma Testing Market, 2021 - 2033 (USD Million)
  • 8.3.4. UK
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Target Disease Prevalence
    • 8.3.4.3. Competitive Scenario
    • 8.3.4.4. Regulatory Framework
    • 8.3.4.5. Reimbursement Scenario
    • 8.3.4.6. UK Mycoplasma Testing Market, 2021 - 2033 (USD Million)
  • 8.3.5. France
    • 8.3.5.1. Key Country Dynamics
    • 8.3.5.2. Target Disease Prevalence
    • 8.3.5.3. Competitive Scenario
    • 8.3.5.4. Regulatory Framework
    • 8.3.5.5. Reimbursement Scenario
    • 8.3.5.6. France Mycoplasma Testing Market, 2021 - 2033 (USD Million)
  • 8.3.6. Italy
    • 8.3.6.1. Key Country Dynamics
    • 8.3.6.2. Target Disease Prevalence
    • 8.3.6.3. Competitive Scenario
    • 8.3.6.4. Regulatory Framework
    • 8.3.6.5. Reimbursement Scenario
    • 8.3.6.6. Italy Mycoplasma Testing Market, 2021 - 2033 (USD Million)
  • 8.3.7. Spain
    • 8.3.7.1. Key Country Dynamics
    • 8.3.7.2. Target Disease Prevalence
    • 8.3.7.3. Competitive Scenario
    • 8.3.7.4. Regulatory Framework
    • 8.3.7.5. Reimbursement Scenario
    • 8.3.7.6. Spain Mycoplasma Testing Market, 2021 - 2033 (USD Million)
  • 8.3.8. Denmark
    • 8.3.8.1. Key Country Dynamics
    • 8.3.8.2. Target Disease Prevalence
    • 8.3.8.3. Competitive Scenario
    • 8.3.8.4. Regulatory Framework
    • 8.3.8.5. Reimbursement Scenario
    • 8.3.8.6. Denmark Mycoplasma Testing Market, 2021 - 2033 (USD Million)
  • 8.3.9. Sweden
    • 8.3.9.1. Key Country Dynamics
    • 8.3.9.2. Target Disease Prevalence
    • 8.3.9.3. Competitive Scenario
    • 8.3.9.4. Regulatory Framework
    • 8.3.9.5. Reimbursement Scenario
    • 8.3.9.6. Sweden Mycoplasma Testing Market, 2021 - 2033 (USD Million)
  • 8.3.10. Norway
    • 8.3.10.1. Key Country Dynamics
    • 8.3.10.2. Target Disease Prevalence
    • 8.3.10.3. Competitive Scenario
    • 8.3.10.4. Regulatory Framework
    • 8.3.10.5. Reimbursement Scenario
    • 8.3.10.6. Norway Mycoplasma Testing Market, 2021 - 2033 (USD Million)
• 8.4. Asia Pacific
  • 8.4.1. SWOT Analysis
  • 8.4.2. Asia Pacific Mycoplasma Testing Market, 2021 - 2033 (USD Million)
  • 8.4.3. Japan
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Target Disease Prevalence
    • 8.4.3.3. Competitive Scenario
    • 8.4.3.4. Regulatory Framework
    • 8.4.3.5. Reimbursement Scenario
    • 8.4.3.6. Japan Mycoplasma Testing Market, 2021 - 2033 (USD Million)
  • 8.4.4. China
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Target Disease Prevalence
    • 8.4.4.3. Competitive Scenario
    • 8.4.4.4. Regulatory Framework
    • 8.4.4.5. Reimbursement Scenario
    • 8.4.4.6. China Mycoplasma Testing Market, 2021 - 2033 (USD Million)
  • 8.4.5. India
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Target Disease Prevalence
    • 8.4.5.3. Competitive Scenario
    • 8.4.5.4. Regulatory Framework
    • 8.4.5.5. Reimbursement Scenario
    • 8.4.5.6. India Mycoplasma Testing Market, 2021 - 2033 (USD Million)
  • 8.4.6. South Korea
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Target Disease Prevalence
    • 8.4.6.3. Competitive Scenario
    • 8.4.6.4. Regulatory Framework
    • 8.4.6.5. Reimbursement Scenario
    • 8.4.6.6. South Korea Mycoplasma Testing Market, 2021 - 2033 (USD Million)
  • 8.4.7. Australia
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Target Disease Prevalence
    • 8.4.7.3. Competitive Scenario
    • 8.4.7.4. Regulatory Framework
    • 8.4.7.5. Reimbursement Scenario
    • 8.4.7.6. Australia Mycoplasma Testing Market, 2021 - 2033 (USD Million)
  • 8.4.8. Thailand
    • 8.4.8.1. Key Country Dynamics
    • 8.4.8.2. Target Disease Prevalence
    • 8.4.8.3. Competitive Scenario
    • 8.4.8.4. Regulatory Framework
    • 8.4.8.5. Reimbursement Scenario
    • 8.4.8.6. Thailand Mycoplasma Testing Market, 2021 - 2033 (USD Million)
• 8.5. Latin America
  • 8.5.1. SWOT Analysis
  • 8.5.2. Latin America Mycoplasma Testing Market, 2021 - 2033 (USD Million)
  • 8.5.3. Brazil
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Target Disease Prevalence
    • 8.5.3.3. Competitive Scenario
    • 8.5.3.4. Regulatory Framework
    • 8.5.3.5. Reimbursement Scenario
    • 8.5.3.6. Brazil Mycoplasma Testing Market, 2021 - 2033 (USD Million)
  • 8.5.4. Argentina
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Target Disease Prevalence
    • 8.5.4.3. Competitive Scenario
    • 8.5.4.4. Regulatory Framework
    • 8.5.4.5. Reimbursement Scenario
    • 8.5.4.6. Argentina Mycoplasma Testing Market, 2021 - 2033 (USD Million)
• 8.6. MEA
  • 8.6.1. SWOT Analysis
  • 8.6.2. MEA Mycoplasma Testing Market, 2021 - 2033 (USD Million)
  • 8.6.3. South Africa
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Target Disease Prevalence
    • 8.6.3.3. Competitive Scenario
    • 8.6.3.4. Regulatory Framework
    • 8.6.3.5. Reimbursement Scenario
    • 8.6.3.6. South Africa Mycoplasma Testing Market, 2021 - 2033 (USD Million)
  • 8.6.4. Saudi Arabia
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Target Disease Prevalence
    • 8.6.4.3. Competitive Scenario
    • 8.6.4.4. Regulatory Framework
    • 8.6.4.5. Reimbursement Scenario
    • 8.6.4.6. Saudi Arabia Mycoplasma Testing Market, 2021 - 2033 (USD Million)
  • 8.6.5. UAE
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Target Disease Prevalence
    • 8.6.5.3. Competitive Scenario
    • 8.6.5.4. Regulatory Framework
    • 8.6.5.5. Reimbursement Scenario
    • 8.6.5.6. UAE Mycoplasma Testing Market, 2021 - 2033 (USD Million)
  • 8.6.6. Kuwait
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Target Disease Prevalence
    • 8.6.6.3. Competitive Scenario
    • 8.6.6.4. Regulatory Framework
    • 8.6.6.5. Reimbursement Scenario
    • 8.6.6.6. Kuwait Mycoplasma Testing Market, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Strategy Mapping
  • 9.2.1. 10.2.1 New Product Launch
  • 9.2.2. 10.2.2 Partnerships
  • 9.2.3. 10.2.3 Acquisition
  • 9.2.4. 10.2.4 Collaboration
  • 9.2.5. 10.2.5 Funding
• 9.3. Key Company Market Share Analysis, 2024
• 9.4. Company Profiles
  • 9.4.1. Thermo Fisher Scientific, Inc.
    • 9.4.1.1. Company overview
    • 9.4.1.2. Financial performance
    • 9.4.1.3. Product benchmarking
    • 9.4.1.4. Strategic Initiatives
  • 9.4.2. Merck & Co., Inc.
    • 9.4.2.1. Company overview
    • 9.4.2.2. Financial performance
    • 9.4.2.3. Product benchmarking
    • 9.4.2.4. Strategic Initiatives
  • 9.4.3. Lonza Group AG
    • 9.4.3.1. Company overview
    • 9.4.3.2. Financial performance
    • 9.4.3.3. Product benchmarking
    • 9.4.3.4. Strategic Initiatives
  • 9.4.4. Charles River Laboratories International, Inc.
    • 9.4.4.1. Company overview
    • 9.4.4.2. Financial performance
    • 9.4.4.3. Product benchmarking
    • 9.4.4.4. Strategic Initiatives
  • 9.4.5. PromoCell GmbH
    • 9.4.5.1. Company overview
    • 9.4.5.2. Financial performance
    • 9.4.5.3. Product benchmarking
    • 9.4.5.4. Strategic Initiatives
  • 9.4.6. Asahi Kasei Medical Co., Ltd.
    • 9.4.6.1. Company overview
    • 9.4.6.2. Financial performance
    • 9.4.6.3. Product benchmarking
    • 9.4.6.4. Strategic Initiatives
  • 9.4.7. Sartorius AG
    • 9.4.7.1. Company overview
    • 9.4.7.2. Financial performance
    • 9.4.7.3. Product benchmarking
    • 9.4.7.4. Strategic Initiatives
  • 9.4.8. InvivoGen
    • 9.4.8.1. Company overview
    • 9.4.8.2. Financial performance
    • 9.4.8.3. Product benchmarking
    • 9.4.8.4. Strategic Initiatives
  • 9.4.9. Eurofins Scientific
    • 9.4.9.1. Company overview
    • 9.4.9.2. Financial performance
    • 9.4.9.3. Product benchmarking
    • 9.4.9.4. Strategic Initiatives
  • 9.4.10. (ATCC) American Type Culture Collection
    • 9.4.10.1. Company overview
    • 9.4.10.2. Financial performance
    • 9.4.10.3. Product benchmarking
    • 9.4.10.4. Strategic Initiatives